ClinicalTrials.gg
CompletedNCT05068388Updated May 20, 2026

Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

A Phase 2 interventional study of Z-Endoxifen and Placebo in Breast Density, sponsored by Atossa Therapeutics, Inc.. Completed at 1 site in Sweden. Open to female participants aged 40 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Atossa Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
Female
01

Study summary

This is a randomized, double-blinded, placebo-controlled dose-response efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density. There will be 5 in-clinic visits (Screening, Day 1, Months 1, 3 and 6) and 3 self-report visits (Months 2, 4 and 5). Standard of care mammograms will be used for the screening mammogram as well as the 24-month follow up visit.

02

Conditions studied

  • Breast Density
03

In context

Lead sponsor

Atossa Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Premenopausal women (defined as having at least one menstruation during the prior 12 months; women with an intrauterine device are considered premenopausal if \<52 years)
  2. Women of using a highly effective method of * throughout the study period and willing to comply with monthly pregnancy testing
  3. Screening mammogram performed within 3 month of study inclusion
  4. Mammographic density assessed as BI-RADS® score B, C, or D
  5. Must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects

Exclusion criteria

Exclusion Criteria:

  1. Mammographic BI-RADS® code ≥3 at baseline mammography
  2. Any previous diagnosis of breast cancer, including carcinoma in situ, or any other cancer (non-melanoma skin cancer and in situ cancer of the cervix are not exclusion criteria)
  3. A history of breast surgery, e.g., reduction or enlargement, which might affect mammographic density measurements
  4. Current medical conditions:

    1. APC (activated protein C) resistance, an inherited coagulation disorder
    2. Systolic pressure higher than 160 mm Hg or diastolic higher than 100 mm Hg
    3. Cataract(s)
    4. Uncontrolled diabetes (defined as >50 mmol/mol)
    5. Abnormal lab values deemed by Investigator
  5. > 30
  6. Women who have an increased risk of venous thrombosis due to immobilization, e.g., using wheelchair
  7. Agents that have the potential to decrease endoxifen levels through increased metabolic clearance:

    1. Certain anti-epileptic therapies (carbamazepine, fenytoin, fenobarbital, lamotrigine)
    2. Certain antibiotics (rifamycins)
    3. St John's wort (in Swedish: johannesört)
    4. Certain medications (efavirenz, ritonavir)
  8. Lactating, pregnant, or plan to become pregnant in the next year
  9. History of thromboembolic disease such as embolus, deep vein thrombosis, stroke, (transient ischemic attack) or myocardial infarction
  10. Allergy to endoxifen or any of its components
  11. Previous treatment with an anti-oestrogen, including experimental drug studies (e.g., Karma CREME, Karisma-1 or Karisma-2)
  12. Prescribed and regular use of anticoagulants (defined as substances included in group B01A in the ATC-system)
  13. Participation in another clinical trial in the last 6 months
  14. Not willing or able to understand the study information and/or
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    oral capsule

    Drug: Placebo

  • Experimental
    1 mg (Z)-endoxifen

    oral capsule

    Drug: Z-Endoxifen

  • Experimental
    2 mg (Z)-endoxifen

    oral capsule

    Drug: Z-Endoxifen

Interventions

06

What researchers measure

Primary outcomes

  1. Change of mammographic density area (cm2) assessed by iCAD® software

    Change from baseline

    Time frame: 6 months

Secondary outcomes

  1. Change of mammographic density area (cm2) assessed by iCAD® software

    Change from baseline

    Time frame: 3 months

  2. Change of mammographic density area (cm2) assessed by Stratus software

    Change from baseline

    Time frame: 6 months

  3. Change of mammographic density area (cm2) assessed by Stratus software

    Change from baseline

    Time frame: 3 months

  4. Change from baseline responses to the Breast Cancer Prevention Trial Eight Symptom Scale (BESS)

    5-point Likert-type scale

    Time frame: 6 months

  5. Comparison of adverse events

    assessment of adverse events

    Time frame: 6 months

07

Study locations

1 site
  • Karma Study Centre
    Stockholm, Sweden
08

References and documents

Publications

  • Hall P, Hammarstrom M, Bergqvist J, Czene K, Eriksson M, Gabrielson M, Tapia J, Quay S, Nash S, Backlund M. Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial. J Natl Cancer Inst. 2026 Apr 27:djag087. doi: 10.1093/jnci/djag087. Online ahead of print. PubMed 42070780 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jun 2024, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 5, 2021
StartActual
Dec 21, 2021
Primary completionActual
Jun 14, 2024
CompletionActual
Mar 12, 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05068388
Lead sponsor
Atossa Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Dec 21, 2021
Primary completion
Jun 14, 2024
Completion
Mar 12, 2026
Last update
May 20, 2026

Study contacts

Steven Quay, MD
study director · Atossa Therapeutics, Inc.
Per Hall, MD
principal investigator · Södersjukhuset, Stockholm, Sweden

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Endoxifen

Start the discussion